The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Jan SMETANA, Romana ZAORALOVÁ, Renata KUPSKÁ, Kristina BERÁNKOVÁ, Hana FILKOVÁ, Dana KRÁLOVÁ, Jan KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK. The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen. 2008.

Basic information

Original name

The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen

Name in Czech

Nepříznivá prognóza spojená se ziskem 1q21 u relabovaných pacientů s mnohočetným myelomem může být překonán léčbou založenou na Velcade narozdíl od léčby založené na podávání thalidomidu

Authors

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Jan SMETANA, Romana ZAORALOVÁ, Renata KUPSKÁ, Kristina BERÁNKOVÁ, Hana FILKOVÁ, Dana KRÁLOVÁ, Jan KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK

Edition

2008

---

Other information

Language

English

Type of outcome

Uspořádání workshopu

Field of Study

Genetics and molecular biology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

Keywords in English

multiple myeloma; Velcade; thalidomide; gain1q21

Tags

gain1q21, multiple myeloma, Thalidomide, Velcade

---

Abstract

V originále

This study is aimed at comparison of ability to overcome the negative prognostic impact of the most common cytogenetic aberrations by treatment regimens based on Velcade or thalidomide. Both new drugs can overcome negative prognostic impact of all named chromosomal abnormalities except gain1q21. However, difference in PFS median between del 17p13 positive and negative patients is not relevant, because of presence of only 1 patient in negative group. The difference in PFS median in gain1q21 positive and negative patients treated by thalidomide based regimen suggests that thalidomide is not able to overcome negative prognostic impact of gain1q21 in contrary of treatment based on Velcade regimen, which probably may overcome poor prognosis of gain1q21. However this findings has to be confirmed on larger cohort of patients with longer follow-up.

In Czech

Práce pojednáva o schopnosti léčby založené na podávání Velcade nebo thalidomidu překonat nepříznivý vliv zisku 1q21 u relabovaných pacientů s mnohočetným myelomem.

---

Links

LC06027, research and development project	Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS) Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622415, plan (intention)	Name: Molekulární podstata buněčných a tkáňových regulací Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations
MSM0021622434, plan (intention)	Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NR9317, research and development project	Name: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu